Lilly Acquires Vaccine Company to Accelerate Development of Epstein-Barr Virus Vaccines

Lilly Acquires Vaccine Company to Propel Vaccine Development

On May 26, 2026, Vaccine Company, a cutting-edge biotechnology firm focused on creating next-generation vaccines, announced it would be acquired by Lilly. This acquisition marks a pivotal moment in the fight against infectious diseases, specifically targeting the Epstein-Barr Virus (EBV) and its associated health risks.

A New Era for Vaccine Development

Vaccine Company is renowned for its proprietary In Vivo Nanoparticle (IVN) technologies. These innovations promise to enhance immune responses by mimicking virus-like particles, thus sidestepping many of the traditional production challenges associated with vaccine manufacturing. The focus of their lead program is a five-antigen vaccine candidate targeted at EBV, which is known for its potential to cause infectious mononucleosis along with more severe long-term complications, such as multiple sclerosis and various cancers. By preventing EBV infection, this vaccine could reduce the incidence of numerous serious health issues.

Terms of the Acquisition

Under the terms of the agreement, Lilly will fully acquire Vaccine Company, with total payments potentially reaching $1.55 billion based on the company's performance against clinical and commercial milestones. This partnership is poised to leverage the strengths of both organizations in order to streamline the development and delivery of critical vaccine solutions.

Leadership Voices

Susan Silbermann, CEO of Vaccine Company, expressed her enthusiasm about the acquisition, stating, “Our pipeline of programs, coupled with our proprietary In Vivo Nanoparticle (IVN) technologies, have the potential for global impact. Together with Lilly, we will be positioned to advance our science, move programs through development, and ultimately deliver vaccines to people around the world.”

Similarly, Daniel M. Skovronsky, MD, Ph.D., Chief Scientific Officer at Lilly, acknowledged the significance of this venture. He remarked, “Epstein-Barr virus is among the most prevalent human viruses globally, yet we do not yet have a vaccine against it. Vaccine Company has built a platform we believe may be capable of changing that.” He emphasized that preventing EBV infection is vital, as it could significantly lower the long-term disease burden linked to this virus.

Transaction Conditions and Advisors

The deal remains contingent upon customary conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Financial matters are being handled by Lazard, which serves as the exclusive financial advisor, while Cooley LLP acts as legal counsel to Vaccine Company.

About Vaccine Company

Founded in 2022 with the backing of renowned investors including ARCH Venture Partners and Pfizer Ventures, Vaccine Company has quickly emerged as a leader in antigen engineering for vaccines. Its pipeline reflects a dedicated effort to combat various viral infections, utilizing innovative approaches that combine the best aspects of existing vaccine technologies. With the acquisition by Lilly on the horizon, the company stands on the brink of achieving significant advancements in healthcare innovation, bringing hope for effective vaccines against EBV and beyond.

Conclusion

As the world continues to grapple with infectious diseases, the acquisition of Vaccine Company by Lilly symbolizes a important advancement in vaccine research and development. This collaboration aims to not only introduce effective vaccines for EBV but also lay the groundwork for addressing other infectious diseases in the future. The scientific community and healthcare advocates are watching closely, hopeful that this partnership will lead to groundbreaking solutions that can save lives around the globe.